Outcomes associated with the high sensitivity cardiac troponin testing in patients presenting with non-cardiovascular disorders.


Journal

The American journal of emergency medicine
ISSN: 1532-8171
Titre abrégé: Am J Emerg Med
Pays: United States
ID NLM: 8309942

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 02 09 2021
revised: 20 10 2021
accepted: 22 10 2021
pubmed: 18 11 2021
medline: 30 12 2021
entrez: 17 11 2021
Statut: ppublish

Résumé

There are limited data regarding the utility of troponin testing in patients presenting with non-cardiovascular (CV) symptoms as the primary manifestation. The study population comprised 2057 patients who presented to the emergency department (ED) of a US healthcare system with non-CV symptoms as the primary manifestation between January and September 2018. We compared the effect of high-sensitivity cardiac troponin T (hs-cTnT) (n = 901) after its introduction vs. 4th generation cTnT (n = 1156) on the following outcomes measures: ED length of stay (LOS), coronary tests/procedures (angiography or stress test), and long-term mortality. Mean age was 64 ± 17 yrs., and 47% were female. Primary non-CV manifestations included pneumonia, obstructive pulmonary disease, infection, abdominal-complaint, and renal failure. Mean follow up was 9 ± 4 months. Patients' demographics and medical history were clinically similar between the two troponin groups. A second cTn test was obtained more frequently in the hs-cTnT than cTnT (84% vs. 32%; p < 0.001), possibly leading to a longer ED stay (8.1 ± 8.2 h vs 5.6 ± 3.4 h, respectively; p < 0.001). Coronary tests/procedures were performed at a significantly higher rate in the hs-cTnT than cTnT following the introduction of the hs-cTnT test (28% vs. 22%, p < 0.001). Multivariate analysis showed that following the introduction of hs-cTnT testing, there was a significant 27% lower risk of long-term mortality from ED admission through follow-up (HR = 0.73, 95%CI 0.54-0.98; p = 0.035). In conclusion, we show that in patients presenting primarily with non-CV disorders, the implementation of the hs-cTnT was associated with a higher rate of diagnostic coronary procedures/interventions, possibly leading to improved long-term survival rates.

Identifiants

pubmed: 34785483
pii: S0735-6757(21)00871-8
doi: 10.1016/j.ajem.2021.10.037
pii:
doi:

Substances chimiques

Biomarkers 0
Troponin T 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

280-284

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

May Goldenberg (M)

Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, NY, United States of America.

Adnan Kharsa (A)

Department of Internal Medicine, Rochester General Hospital, Rochester, NY, United States of America.

Shamroz Farooq (S)

Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, NY, United States of America.

John D Bisognano (JD)

Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, NY, United States of America.

Andrew Mathias (A)

Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, NY, United States of America.

Scott McNitt (S)

Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, NY, United States of America.

Anita Y Chen (AY)

Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, NY, United States of America; Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, United States of America.

Arwa Younis (A)

Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, NY, United States of America; Department of Cardiology, Cleveland Clinic, Cleveland, OH, United States of America. Electronic address: or.younis@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH